Biotech
Tune Therapeutics
Tune Therapeutics raises $175M Series B at $900M valuation
$175M
Total Raised
Series B
Latest Round
2021
Founded
100+
Employees
Durham, NC
1 min read
Quick Facts
Valuation
$900M
Latest Round Size
$175M
Latest Round Date
February 2025
Tune Therapeutics: Series B Funding Round
Tune Therapeutics has successfully raised $175M in Series B funding, reaching a valuation of $900M.
Company Overview
Epigenetic gene regulation therapies
Funding Details
The Series B round was led by Hevolution, with participation from NEA, Regeneron Ventures.
Company Information
- Headquarters: Durham, NC
- Founded: 2021
- Employees: 100+
- Category: Biotech
Investment
Tune Therapeutics plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- Hevolution: Verified investor in Series B
- NEA: Verified investor in Series B
- Regeneron Ventures: Verified investor in Series B
Key Investors
Hevolution
Lead Investor
Verified investor in Series B
NEA
Investor
Verified investor in Series B
Regeneron Ventures
Investor
Verified investor in Series B
About the Author
Editorial Team
Curated funding news from verified sources
Related Company Reports
Biotech
Orna Therapeutics
Orna Therapeutics Raises $251M Series B
Biotechnology company developing circular RNA therapeutics for cancer, genetic diseases, and infectious diseases
Emma Rodriguez
Oct 23, 2025
0 min read•$251M Series B
Biotech
Forge Biologics
Forge Biologics Raises $120M Series C
Gene therapy CDMO providing manufacturing and development services for AAV-based genetic medicines
Sarah Kim
Oct 23, 2025
0 min read•$120M Series C
Biotech
Vir Biotechnology
Vir Biotechnology Raises $250M
Clinical-stage immunology company developing treatments for infectious diseases including COVID-19, hepatitis B, and influenza
Sarah Kim
Oct 23, 2025
0 min read•$250M